Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Exclusively Distribute 454 s Sequencing Tech; Rothberg Steps Down

NEW YORK, May 12 (GenomeWeb News) - 454 Life Sciences has signed an exclusive distribution agreement with Roche for its sequencing technology in a deal potentially worth $62 million to the sequencing upstart. 454 has also named a new chief executive as CuraGen Jonathan Rothberg has stepped down.

 

Under their five-year worldwide agreement, Roche Applied Science, a business area of Roche Diagnostics, will sell 454's nanotechnology-based genome sequencing systems, including kits and reagents. It will distribute the products through Roche Diagnostics' supply chain, and provide technical support.

 

454 will receive up to $62 million in license fees, milestones for instrument releases, minimum royalties and research funding. It will also receive a margin on products manufactured for Roche Diagnostics, as well as royalties on net sales of licensed products.

 

Roche can sell the products to all markets except for "regulated diagnostics." Roche has the option, though, to negotiate for an expansion of the agreement within the next five years to include this market. It may also renew the agreement after five years if certain undisclosed performance criteria are met.

 

According to Peter Dacey, 454's vice president of finance, the company currently only focuses on research applications for the technology, but believes "there is a future potential" in diagnostics.

 

454 Life Sciences, a subsidiary of CuraGen, will manufacture the instruments and reagent kits. If sales ramp up, Roche Diagnostics may start manufacturing the reagents.

 

Separately, 454 said today it has named Christopher McLeod as its president and CEO. McLeod is an executive vice presdent of CuraGen. Jonathan Rothberg has stepped down as CEO of CuraGen to become chairman of the board of 454 Life Sciences. He is replaced by Patrick Zenner, a CuraGen board member, on an interim basis until a new CEO has been found.

 

The sequencing technology developed by 454 allows users to sequence over 5 million nucleotide bases per hour. It is based on picoliter-technologies, light emitting sequencing chemistries, and informatics.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.